BOSUN Bets on Dividends Over Genomics

by

Let me be clear: I’ve never owned a single share of a company that didn’t send me a check in April. My neighbor, however, recently bought a stock that “outperformed the S&P by 68 points.” I asked him how it paid him back. He said, “It’s a growth play.” I nodded, wondering if he’d ever heard of compound interest.

BOSUN Asset Management, LLC recently filed with the SEC that it sold all 69,858 shares of GeneDx Holdings Corp. (WGS +0.26%)-a tidy $6.45 million exit. For a fund that once held it at 1.9% of its AUM, this feels less like a panic sell and more like a polite thank-you for a ride that never included a seatbelt. Or dividends. Or any real sense of financial security.

What Else to Know

After the filing, BOSUN’s top holdings read like a grocery list for the tech-obsessed: AMZN, AAPL, CBOE, GS, and META. It’s the kind of portfolio that makes you wonder if the fund managers still remember what a dividend yield looks like. Their GeneDx stake, meanwhile, vanished like my hopes for a stable retirement fund after the 2008 crash.

  • Top holdings post-filing:
    • AMZN: $24.7 million (12.6% of AUM)
    • AAPL: $19.3 million (9.9% of AUM)
    • CBOE: $18.9 million (9.7% of AUM)
    • GS: $13.5 million (6.8% of AUM)
    • META: $8.4 million (4.3% of AUM)

As of November 12, 2025, GeneDx’s shares traded at $141.90, up 84.6% over the past year. That’s impressive until you realize the stock still doesn’t pay a dividend. I once owned a company that paid 5% annually. It was called “the bank.”

Company Overview

Metric Value
Price (as of November 12,2025) $141.90
1-Year Price Change 84.6%
Dividend Yield N/A

Company Snapshot

  • GeneDx sells itself as a “health intelligence” company, using AI to analyze genomic data. I’m all for innovation, but when was the last time your DNA sent you a quarterly dividend? Never? Exactly.
  • Their “proprietary platform” is powered by a dataset of nearly one million exomes and seven million phenotypic data points. Sounds thrilling until you realize it’s just a fancy way of saying, “We have a lot of numbers.”
  • Revenue comes from healthcare providers and research institutions. Which is to say: people who care more about science than cash flow. A dangerous combo if you’re a dividend hunter.

Foolish Take

BOSUN’s exit from GeneDx is the financial equivalent of leaving a party before the host starts playing karaoke. The stock’s 80% gain is admirable, but without a dividend, it’s just a fireworks show with no sparklers for investors. I’ve seen too many growth stocks burn out faster than a candle in a hurricane. My money’s on the old reliables-companies that send checks, not just charts.

GeneDx’s future in genomics is bright, sure, but so was the dot-com bubble. I prefer my innovations with a side of stability. After all, what good is a 100% stock return if you can’t cash it in for groceries? My cousin tried that strategy. He now buys his insulin with Bitcoin.

The biotech sector is a rollercoaster, and BOSUN just stepped off at the top of the hill. For a fund that once held this as a smaller position, it’s a calculated move. But for dividend hunters like me? It’s a reminder that not every high-flying stock is worth the turbulence. Some of us just want a quiet ride to retirement.

Glossary

13F: A quarterly report filed by institutional investment managers disclosing their equity holdings to the SEC. It’s like a financial diary, but with fewer personal revelations.
Assets Under Management (AUM): The total market value of investments managed by a fund or firm on behalf of clients. Think of it as the weight of your financial dreams, measured in dollars.
Stake: The amount of ownership or investment a fund or individual holds in a particular company. Also the word I use when I’m trying to sound sophisticated at family dinners.
Position: The amount of a particular security or asset held by an investor or fund. A term that makes selling shares sound like a military strategy.
Exited its stake: Sold all holdings in a particular company, reducing ownership to zero. A phrase that makes it sound less like a loss and more like a well-timed escape.
Form 13F: The specific SEC filing used by institutional managers to report their investment holdings. A bureaucratic document that makes me miss the days of handwritten ledgers.
Quarterly average pricing: The average price of a security over a three-month reporting period. A concept I still struggle to explain to my mother.
Outperforming: Achieving a higher return compared to a benchmark or index over a given period. A term that makes me check my dividend statements twice.
Genomic data: Information related to an individual’s complete set of genes, used for medical analysis and research. A phrase that sounds futuristic until you realize it’s mostly just data.
Health intelligence solutions: Technology-driven tools that analyze health data to provide insights for patient care and disease management. A buzzword that makes me crave something simpler, like a thermometer.
TTM: The 12-month period ending with the most recent quarterly report. A metric that makes me feel old.
Downsizing: Reducing the size or value of a fund’s portfolio, often by selling assets. A euphemism for “we’re cutting our losses.”

Still think growth stocks are the way to go? I say keep the checks coming. 😅

Read More

2025-11-14 22:02